scholarly journals Sustained Posttransplantation Diabetes Is Associated With Long-Term Major Cardiovascular Events Following Liver Transplantation

2017 ◽  
Vol 18 (1) ◽  
pp. 207-215 ◽  
Author(s):  
G. A. Roccaro ◽  
D. S. Goldberg ◽  
W.-T. Hwang ◽  
R. Judy ◽  
A. Thomasson ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Cardiovascular Events ◽  
Major Cardiovascular Events

scholarly journals Serum adipokine and inflammatory markers before and after liver transplantation in recipients with major cardiovascular events

2014 ◽  
Vol 20 (7) ◽  
pp. 791-797 ◽  
Author(s):  
Kymberly D. Watt ◽  
Chun Fan ◽  
Terry Therneau ◽  
Julie K. Heimbach ◽  
Eric C. Seaberg ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Inflammatory Markers ◽  
Cardiovascular Events ◽  
Major Cardiovascular Events ◽  
Before And After

P6448Major cardiovascular events free survival in the long term follow up of “real world” diabetic patients with stable coronary artery disease at the beginning of the 21st century. The CICCOR Registry

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
M Ruiz Ortiz ◽  
J J Sanchez Fernandez ◽  
C Ogayar Luque ◽  
E Romo Penas ◽  
M Delgado Ortega ◽  
...  
Keyword(s):  
Real World ◽  
Cardiovascular Events ◽  
Stable Coronary Artery Disease ◽  
Diabetic Patients ◽  
Free Survival ◽  
End Point ◽  
Major Cardiovascular Events ◽  
Artery Disease

Abstract Background Safety trials of antidiabetic drugs have included a main endpoint of cardiovascular morbidity and mortality. However, “real world” data on long term prognosis of diabetic patients with stable coronary artery disease (sCAD) are limited. This study aimed to assess long-term incidence of major cardiovascular events in this population and to identify clinical predictors of this end-point. Methods The CICCOR registry is a prospective, monocentric, cohort study. From February 1, 2000 to January 31, 2004, all consecutive patients with sCAD attended at two outpatient cardiology clinics in a city of the south of Spain were included in the study and prospectively followed. Patients with type 2 diabetes mellitus were selected for this analysis. None of these patients received sodium-glucose cotransporter-2 inhibitors at first visit, as they were not commercially available at that time. Survival free of major cardiovascular events (combined end-point: acute myocardial infarction, stroke, or cardiovascular death) and variables associated with this end-point were investigated. Results The study sample included 394 patients (mean age 68±9 years, 61% male). After up to 17 years of follow-up (median 9 years, IQR 4–14 years, only 2 patients lost in follow-up, with a total of 3517 patients-years of observation), 66 had an acute myocardial infarction, 55 had an stroke and 165 died for cardiovascular causes. Survival free of major cardiovascular events was 88%, 70%, 57%, 47% and 32% at 3, 6, 9, 12 and 15 years. Multivariate predictors of the combined end-point are shown in the table. Predictors of major cardiovascular event Variable Hazard Ratio (95% CI) p value Age (year) 1.06 (1.04–1.08) <0.0005 Tobacco use 0.02 Never smoker 1 (reference) Ex-smoker 1.43 (1.02–1.99) 0.04 Active smoker 2.23 (1.16–4.30) 0.02 Functional Class ≥II (angina) 1.57 (1.14–2.16) 0.006 Resting heart rate (10 bpm increase) 1.12 (1.01–1.24) 0.04 Diuretic treatment at first visit 1.71 (1.26–2.30) 0.001 Conclusions Probability of major event-free survival was only 47% at 12 years in this “real world” cohort of diabetic patients with sCAD followed in the first 17 years of this century in a single center in the south of Spain. Simple clinical variables can identify patients at higher risk of events. Acknowledgement/Funding This work has been partially financed by an investigational grant by Boehringher Ingelheim

scholarly journals Incidence, Predictors, and Impact on Survival of Long-term Cardiovascular Events After Liver Transplantation

2020 ◽  
Vol 104 (2) ◽  
pp. 317-325 ◽  
Author(s):  
Lydia Sastre ◽  
Raquel García ◽  
Julián-Gonzalo Gándara ◽  
Pablo Ruiz ◽  
Julissa Lombardo ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Cardiovascular Events ◽  
Impact On Survival

scholarly journals Evaluation of “Sophia Diabetes”, a diabetic patient support programme, 8 years after its initiation

2019 ◽  
Vol 29 (Supplement_4) ◽  
Author(s):  
R Cash ◽  
M Cavillon ◽  
C Leboucher ◽  
B Jouaneton ◽  
A Vainchtock ◽  
...  
Keyword(s):  
Health Insurance ◽  
Disease Management ◽  
Cardiovascular Events ◽  
Positive Impact ◽  
Management Program ◽  
First Year ◽  
Patient Support ◽  
Major Cardiovascular Events

Abstract Background “Sophia Diabetes” is a personalized diabetic patient support program piloted by French National Health Insurance, launched experimentally in 10 primary health insurance funds in March 2008, extended in 2010 and then generalized to all of France in 2012-2013. A new evaluation was performed in 2018 to determine long-term (2008-2016) improvement of medical follow-up indicators, impact on morbidity, mortality and healthcare expenditure. Methods A sample of patients (n = 49,016) eligible for the programme in 2008, but also a sub-group of participating patients (n = 17,007), was matched, using propensity score, with controls randomly selected from the SNDS. Difference in difference method was applied for comparisons at each year of follow-up (Ti) while controlling for differences between populations. Results Sophia had a significant positive impact on recommended follow-up indicators, right from the first year. This improvement was maintained for most indicators even if compliance rates remained lower than targets. Sophia Diabetes does not appear to have a major impact on hospitalization rates in either eligible patients or participating patients. However, comparison between participants and controls revealed a less marked increase of hospitalizations for major cardiovascular events at T6 and T7. Compared to their controls, a better use of hospital emergency departments was observed for participants. Ambulatory care expenditure of participants increased more markedly between T4 and T7 (+€105 to €233), related to a better follow-up but in contrast, hospital expenditure increased less markedly during the first year of follow-up (-€139) and the last 2 years (-€360 to -€380). Conclusions For the first time in France, a disease management program has been evaluated over a long period. Globally, Sophia programresults in improved patient follow-up, decreased emergency visits, and a less marked increase of hospitalizations for major cardiovascular events at the end of period. Key messages First long term evaluation (8 years) of a disease management program in France. Sophia diabetes management program shows a positive impact on some follow-up and morbidity indicators.

Influence of sleep disturbances on age at onset and long-term incidence of major cardiovascular events: the MONICA-Brianza and PAMELA cohort studies

2016 ◽  
Vol 21 ◽  
pp. 126-132 ◽  
Author(s):  
Francesco Gianfagna ◽  
Giovanni Veronesi ◽  
Lorenza Bertù ◽  
Giancarlo Cesana ◽  
Guido Grassi ◽  
...  
Keyword(s):  
Cohort Studies ◽  
Cardiovascular Events ◽  
Sleep Disturbances ◽  
Age At Onset ◽  
Major Cardiovascular Events

On-treatment blood pressure and long-term outcomes in chronic kidney disease

2021 ◽  
Author(s):  
Hae Hyuk Jung
Keyword(s):  
Cardiovascular Events ◽  
Composite Outcome ◽  
Long Term Outcomes ◽  
Major Cardiovascular Events ◽  
Hazard Ratios ◽  
All Cause Mortality ◽  
Composite Risk ◽  
Information Database

ABSTRACT Background The treatment BP target in CKD remains unclear, and whether the benefit of intensive BP-lowering is comparable between CKD and non-CKD patients is debated. Methods Using the Korean National Health Information Database, 359,492 CKD patients who had received antihypertensives regularly were identified from 12.1 million participants of nationwide health screening. The composite risk of major cardiovascular events, kidney failure, and all-cause mortality was assessed according to timely-averaged, on-treatment systolic BP. Results Over 9-year follow-up, the composite outcome noted in 18.4% of 239,700 participants with eGFR &lt;60 ml/min/1.73 m2 and 18.9% of 155,004 with dipstick albuminuria. The thresholds of systolic BP, above which the composite risk increased significantly, in the reduced eGFR and the proteinuric population were 135 mm Hg and 125 mm Hg, respectively. For all-cause mortality, the respective thresholds were 145 mm Hg and 135 mm Hg. When comparing the composite risk between propensity score-matched groups, the hazard ratios of on-treatment BP of systolic 135–144 mm Hg (reference, 115–124 mm Hg) in the reduced eGFR and non-CKD pairs were 1.18 and 0.98, respectively (P = 0.13 for interaction), and those in the proteinuria and non-CKD pairs were 1.30 and 1.01, respectively (P = 0.003 for interaction). Conclusions The findings support the recommendation that, based on office BP, the systolic target in CKD with proteinuria is ≤ 130 mm Hg, and the target in CKD with no proteinuria is ≤ 140 mm Hg. The benefit of intensive BP-lowering may be greater in CKD patients particularly with proteinuria than in their non-CKD counterparts.

Sign in / Sign up

Export Citation Format

Share Document